← Leaderboards
Joseph J. Muenzer
University Of North Carolina Chapel Hill
$1,130,475
Attributed
$1,130,475
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $215.8K · FY2005–08$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,130,475 · 9
By mechanism
M01$1,130,475 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Haiyan Fu$5,284,175
- Douglas M McCarty$10,391,159
- Jeffrey Haskell Fair$1,867,809
- Timothy Charles Nichols$20,287,823
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationEnzyme TherapyO GlycosidaseMucopolysaccharidosis Type IChild (0-11)United States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseEnzymesFundingGrantIduronate-2-SulfataseInstitutionMucopolysaccharidosis IiResearch PersonnelResourcesSafetySourceMucopolysaccharidosis Type IiEffectivenessEnzyme Replacement TherapyReplacement TherapyIdursulfase
Grant awards (20)
TKT024EXT: MPS II PATIENTS RECEIVING IDURONATE-2-SULFATASE ENZYME REPLACEMENT$1,301
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: MAINTENANCE STUDY OF IDURONATE-2-SULFATASE REPLACEMENT THERAPY I$153
M01 · FY2008 · RR · contact PI
TKT024EXT: MPS II PATIENTS RECEIVING IDURONATE-2-SULFATASE ENZYME REPLACEMENT$22,510
M01 · FY2007 · RR · contact PI
MAINTENANCE STUDY OF IDURONATE-2-SULFATASE REPLACEMENT THERAPY IN MPS II PATIENT$5,252
M01 · FY2007 · RR · contact PI
TKT024EXT: MPS II PATIENTS RECEIVING IDURONATE-2-SULFATASE ENZYME REPLACEMENT$80,781
M01 · FY2006 · RR · contact PI
BI-WEEKLY DOSING REGIMENS OF IDURONATE-2-SULFATASE ENZYME REPLACEMENT MPS II$13,877
M01 · FY2006 · RR · contact PI
MAINTENANCE STUDY OF IDURONATE-2-SULFATASE REPLACEMENT THERAPY IN MPS II PATIENT$8,921
M01 · FY2006 · RR · contact PI
BI-WEEKLY DOSING REGIMENS OF IDURONATE-2-SULFATASE ENZYME REPLACEMENT MPS II$185,351
M01 · FY2005 · RR
MAINTENANCE STUDY OF IDURONATE-2-SULFATASE REPLACEMENT THERAPY IN MPS II PATIENT$27,645
M01 · FY2005 · RR
TKT024EXT: MPS II PATIENTS RECEIVING IDURONATE-2-SULFATASE ENZYME REPLACEMENT$2,827
M01 · FY2005 · RR
Maintenance Study of Iduronate-2-Sulfatase Replacement Therapy in MPS II Patient$82,642
M01 · FY2004 · RR
Bi-Weekly Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement MPS II$21,793
M01 · FY2004 · RR
MPS II: Validation of Childhood Health Assessment Questionnaire$1,132
M01 · FY2004 · RR
ENZYME REPLACEMENT THERAPY FOR PATIENT W/ MUCOPOLYSACCHARIDOSIS I$190,747
M01 · FY2002 · RR
ENZYME REPLACEMENT THERAPY FOR PATIENT W/ MUCOPOLYSACCHARIDOSIS I$294,555
M01 · FY2001 · RR
ENZYME REPLACEMENT THERAPY FOR PATIENT W/ MUCOPOLYSACCHARIDOSIS I$190,747
M01 · FY2001 · RR
ENZYME REPLACEMENT THERAPY FOR PATIENT W/ MUCOPOLYSACCHARIDOSIS I$241
M01 · FY2000 · RR
ENZYME REPLACEMENT THERAPY FOR PATIENT W/ MUCOPOLYSACCHARIDOSIS I$0
M01 · FY2000 · RR
ENZYME REPLACEMENT THERAPY FOR PATIENT W/ MUCOPOLYSACCHARIDOSIS I$0
M01 · FY2000 · RR
ENZYME REPLACEMENT THERAPY FOR PATIENT W/ MUCOPOLYSACCHARIDOSIS I$0
M01 · FY2000 · RR